|
66
|
231
|
4qwlE |
Ycp beta5-a50v mutant in complex with carfilzomib |
|
58
|
222
|
4qw4H |
Ycp in complex with carfilzomib |
|
69
|
242
|
4qv4D |
Ycp beta5-m45t mutant |
|
64
|
231
|
4qz7E |
Ycp beta5-a50v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
66
|
242
|
4qxjD |
Ycp beta5-m45a mutant in complex with the epoxyketone inhibitor onx 0914 |
|
71
|
243
|
4qw5F |
Ycp beta5-m45a mutant in complex with carfilzomib |
|
68
|
242
|
4qvnD |
Ycp beta5-m45v mutant in complex with bortezomib |
|
71
|
240
|
4r00C |
Ycp beta5-c52f mutant in complex with omuralide |
|
65
|
244
|
4qwgB |
Ycp beta5-a49v mutant in complex with carfilzomib |
|
59
|
222
|
4qluH |
Ycp in complex with tripeptidic epoxyketone inhibitor 9 |
|
75
|
243
|
4r02F |
Ycp in complex with bsc4999 (alpha-keto phenylamide) |
|
67
|
242
|
4qz0D |
Ycp beta5-m45v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
66
|
233
|
4qw5M |
Ycp beta5-m45a mutant in complex with carfilzomib |
|
58
|
222
|
4qvpL |
Ycp beta5-m45t mutant in complex with bortezomib |
|
59
|
222
|
4qwsL |
Ycp beta5-c63f mutant in complex with carfilzomib |
|
70
|
240
|
4qvlC |
Ycp in complex with bortezomib |
|
56
|
204
|
4qwsI |
Ycp beta5-c63f mutant in complex with carfilzomib |
|
65
|
250
|
4qvqA |
Ycp beta5-m45i mutant in complex with bortezomib |
|
72
|
212
|
4qlqK |
Ycp in complex with tripeptidic epoxyketone inhibitor 8 |
|
69
|
242
|
4qzwD |
Ycp beta5-c52f mutant in complex with the epoxyketone inhibitor onx 0914 |
|
67
|
250
|
4qwxA |
Ycp in complex with the epoxyketone inhibitor onx 0914 |
|
69
|
244
|
4qw6B |
Ycp beta5-m45v mutant in complex with carfilzomib |
|
69
|
242
|
4qvlD |
Ycp in complex with bortezomib |
|
66
|
240
|
4r02C |
Ycp in complex with bsc4999 (alpha-keto phenylamide) |
|
60
|
196
|
4qxjN |
Ycp beta5-m45a mutant in complex with the epoxyketone inhibitor onx 0914 |
|
63
|
195
|
4qwfJ |
Ycp beta5-m45i mutant in complex with carfilzomib |
|
56
|
204
|
4qvvI |
Ycp beta5-a49v mutant in complex with bortezomib |
|
65
|
231
|
4qv1E |
Ycp beta5-m45a mutant |
|
65
|
244
|
4r18B |
Ligand-induced lys33-thr1 crosslinking at subunit beta5 of the yeast 20s proteasome |
|
62
|
241
|
4qv5G |
Ycp beta5-m45i mutant |
|
63
|
195
|
4qwlJ |
Ycp beta5-a50v mutant in complex with carfilzomib |
|
66
|
212
|
4qvpK |
Ycp beta5-m45t mutant in complex with bortezomib |
|
58
|
226
|
4qv5H |
Ycp beta5-m45i mutant |
|
60
|
222
|
4r00L |
Ycp beta5-c52f mutant in complex with omuralide |
|
67
|
250
|
4qwuA |
Ycp beta5-c52f mutant in complex with bortezomib |
|
64
|
241
|
4qw1G |
Ycp beta5-a50v mutant in complex with bortezomib |
|
68
|
212
|
4qv9K |
Ycp beta5-c63f mutant |
|
69
|
212
|
4qltK |
Ycp in complex with tripeptidic epoxyketone inhibitor 2 (pr924) |
|
70
|
240
|
4qvmC |
Ycp beta5-m45a mutant in complex with bortezomib |
|
59
|
226
|
4qv1H |
Ycp beta5-m45a mutant |
|
55
|
220
|
4r3oI |
Human constitutive 20s proteasome |
|
71
|
243
|
4qz0F |
Ycp beta5-m45v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
59
|
222
|
4qvyL |
Ycp beta5-a49t-mutant in complex with bortezomib |
|
63
|
241
|
4qv1G |
Ycp beta5-m45a mutant |
|
50
|
204
|
4r67J |
Human constitutive 20s proteasome in complex with carfilzomib |
|
67
|
233
|
4qz2M |
Ycp beta5-m45i mutant in complex with the epoxyketone inhibitor onx 0914 |
|
71
|
240
|
4qv3C |
Ycp beta5-m45v mutant |
|
62
|
195
|
4qz6J |
Ycp beta5-a49t-a50v double mutant in complex with the epoxyketone inhibitor onx 0914 |
|
67
|
244
|
4qwlB |
Ycp beta5-a50v mutant in complex with carfilzomib |
|
67
|
242
|
4qw6D |
Ycp beta5-m45v mutant in complex with carfilzomib |
